DBV Technologies Stock Up +179% Over the Year, But Technical Threshold Curbs Momentum

Current Session Overview

In today's session, DBV Technologies dropped by 2.03% to 3.57 euros, after closing at 3.64 euros the previous day. Over the past week, the stock has lost 4.8%, a moderate correction following a quarter of strong gains: the stock rose by 20.4% over three months and has surged by 179.3% over the year. This movement is part of a broader downtrend in the European stock market. The CAC 40 is down by 0.81% during the session, while the SBF 120 has fallen by 0.78%. Sector peers are also affected: Sanofi is down by 0.36% and UCB by 0.78%. Thus, the French biotech is not immune to the selling pressure affecting the entire health sector this Thursday.

Technical Analysis

Technically, the stock is currently trading below its 50-day moving average, set at 3.69 euros, indicating a slight slowdown in the short-term bullish momentum. However, the price remains well above the 200-day moving average (2.63 euros), confirming the strong upward trend observed over the past year. The Relative Strength Index (RSI), which measures the intensity of recent movements, is at 52, indicating a perfectly neutral territory, far from overbought or oversold zones. The stock is also oscillating within its Bollinger Bands, between the lower bound at 3.22 euros and the upper bound at 3.89 euros. The nearest support is at 3.37 euros, while resistance is found at 4.04 euros, a level that would be a key threshold if the upward momentum resumes.